MEDICA 2026 | 16–19 November 2026 | Hall 6, Stall F37 | Düsseldorf, Germany
A comprehensive examination of internal septum mechanics, infection prevention protocols, regulatory compliance, and total procurement economics for medical device importers and healthcare systems.
In modern acute care and emergency medicine, Peripheral Intravenous Catheter (PIVC) insertion remains the single most common invasive vascular procedure performed worldwide. However, conventional open IV cannulas present significant clinical risks: the immediate backflow of blood during needle withdrawal exposes nurses and clinicians to hazardous blood-borne pathogens (including Hepatitis B, Hepatitis C, and HIV) while dirtying clinical bedding, floor areas, and patient skin. For international procurement managers, hospital group purchasing organizations (GPOs), and medical device distributors, the clinical transition toward a Blood Control Technology IV Catheter is no longer merely a preference—it has become a foundational safety standard backed by strict regulatory frameworks such as the EU Directive 2010/32/EU and US OSHA Bloodborne Pathogens Standards.
The core innovation of Lars Medicare’s Blood Control Technology IV Catheter resides within its internal elastomer septum valve housed securely inside the catheter hub. Unlike standard safety catheters that only encapsulate the sharp tip after withdrawal, a Blood Control catheter acts as a dual-barrier safety system:
Figure 1: Automated assembly of Blood Control IV Catheter hubs under ISO Class 7 cleanroom conditions at our Sonepat facility.
Medical disposables buyers must carefully evaluate catheter shaft materials based on clinical application, indwelling time, and patient vein geometry. Lars Medicare manufactures Blood Control IV Catheters using two premium biocompatible polymers:
FEP catheter tubing provides high structural rigidity and a smooth surface finish, rendering it ideal for quick, firm insertion in emergency rooms and trauma care. It incorporates 3 or 4 radiopaque stripes for clear X-ray visualization, ensuring full compliance with ISO 10555-5 standards.
Polyurethane is thermosensitive; upon insertion into the vein, PUR softens substantially at body temperature. This flexibility reduces mechanical phlebitis, vascular intima irritation, and catheter kink risk, making PUR Blood Control Catheters the preferred choice for long-term indwelling therapy (>48 hours) and pediatric oncology wards.
While the initial unit purchase price of a Blood Control Safety IV Catheter is slightly higher than a basic open cannula, independent health economic studies prove that implementing Blood Control Technology delivers substantial net savings to hospital budgets:
| Cost Factor | Conventional Open Cannula | Lars Blood Control Safety IV Catheter |
|---|---|---|
| Blood Exposure & Spillage | High risk of blood leakage onto bedding, clothing, and clinician gloves. | Zero blood spillage upon needle withdrawal; 95% reduction in blood exposure. |
| Auxiliary Consumable Usage | Requires extra gauze packs, bed pads, protective drapes, and venous compression. | Eliminates the need for digital vein compression and secondary absorbent pads. |
| Clean-up & Nursing Time | 2–5 minutes spent per insertion cleaning blood spillages and replacing soiled linen. | Immediate connection to infusion line without clean-up; saves valuable nursing time. |
| Sharps Injury & Pathogen Risk | High vulnerability during manual compression or two-handed capping steps. | Passive needle shielding + sealed hub completely isolates blood-borne pathogens. |
| Overall System Procurement Economics | Higher hidden costs due to infections, waste disposal, and extended care times. | Significantly lower total cost per successful indwelling vascular access event. |
Precision-manufactured peripheral vascular devices compliant with ISO 10555, CE MDR, and global pharmacopeia standards. Available for immediate worldwide export and private-label OEM programmes.
Integrated internal silicone septum blocks blood backflow upon stylet extraction. Combined with a passive needle safety shield for zero blood exposure and maximum sharps protection.
Features an automatic spring clip mechanism that encapsulates the sharp needle tip instantly upon withdrawal, eliminating needlestick injury risks without manual activation.
All-in-one pre-assembled closed loop system combining catheter, blood control septum, pre-attached extension line, and needle-free valve to minimize bloodstream contamination.
Traditional peripheral IV catheter featuring tri-facet bevelled needle grinding and radio-opaque catheter tubing for smooth venipuncture in high-volume general wards.
Polycarbonate pressure-resistant flow control devices with 360-degree rotating handle for multi-line drug administration alongside Blood Control Catheters.
Gravity and pump infusion sets crafted from phthalate-free compounds. Micro-drip and macro-drip configurations designed for seamless connection to safety catheters.
| Gauge Size | Color Code | Catheter O.D. x Length | Water Flow Rate (mL/min) | Primary Recommended Clinical Application |
|---|---|---|---|---|
| 14G | Orange | 2.1 mm x 45 mm | 290 mL/min | Trauma care, rapid blood transfusion, major surgical fluid resuscitation |
| 16G | Grey | 1.7 mm x 45 mm | 180 mL/min | Emergency department, rapid fluid administration, high-volume infusion |
| 18G | Green | 1.3 mm x 45 mm | 90 mL/min | Routine blood transfusions, pre-operative surgical prep, IV nutrition |
| 20G | Pink | 1.1 mm x 32 mm | 60 mL/min | General ward adult patient infusions, routine IV drug delivery |
| 22G | Blue | 0.9 mm x 25 mm | 36 mL/min | Elderly patients with fragile veins, oncology, small vein access |
| 24G | Yellow | 0.7 mm x 19 mm | 23 mL/min | Pediatrics, neonatology, delicate chemotherapy administration |
| 26G | Violet | 0.6 mm x 19 mm | 15 mL/min | Neonatal intensive care units (NICU), micro-infusions |
What global procurement directors, hospital tender boards, and OEM brand managers must anticipate when structuring long-term supply chain contracts for Blood Control IV Catheters.
While safety needle legislation originated in North America and Western Europe, regulatory bodies across Latin America (ANVISA, COFEPRIS), the Middle East (SFDA), and Asia-Pacific (CDSCO, TGA) are rapidly codifying compulsory sharps protection rules. Future tender specifications will strictly exclude open, non-safety catheters in favor of integrated Blood Control Safety IV Catheters to eliminate hospital-acquired infection (HAI) liabilities.
The global clinical community is increasingly transitioning from standalone IV cannulas to Closed IV Catheter Systems featuring pre-attached extension tubing and blood-control septa. By eliminating extraneous connection steps at the bedside, closed systems reduce vein hub manipulation, lower central line-associated bloodstream infection (CLABSI) risks, and decrease peripheral IV catheter failure rates.
Environmental and clinical safety mandates are driving the elimination of DEHP, TOTM, and toxic plasticizers from vascular access devices. Next-generation Blood Control IV Catheters utilize ultra-pure medical-grade Polyurethane (PUR) and silicone septa that guarantee zero leachability, superior hemocompatibility, and extended dwell times without catheter degradation.
The global medical supply disruptions of recent years demonstrated the vulnerability of relying on trading intermediaries. Importers and hospital chains are shifting procurement budgets toward vertically integrated manufacturers—such as Lars Medicare—that maintain in-house tooling, injection molding, automated cleanroom assembly, and ethylene oxide (EO) sterilization under a single quality management system.
Located in Sonepat (Haryana), our state-of-the-art manufacturing plant spans advanced ISO Class 7 cleanrooms, automated needle grinding suites, and dedicated Ethylene Oxide (EO) sterilization chambers. We manage every step of production internally to maintain absolute batch-to-batch consistency.
Our standardized four-stage process ensures seamless technical alignment, regulatory approval, private label artwork locking, and reliable delivery for tender agents and distributors.
Submit your SKU mix, target market, catheter material choices (FEP vs. PUR), and regulatory dossier requirements. Our technical team provides complete specifications, ISO standards compliance data, and initial quotes.
We dispatch sterile evaluation samples along with batch Certificates of Analysis (CoA) so your quality control team and clinical key opinion leaders can verify puncture force, flow rates, and septum valve performance.
Our graphics team assists with private label blister package design, inner box layout, barcode generation, UDI compliance, and multi-language Instructions for Use (IFU) in accordance with national health regulations.
High-speed automated assembly, EO sterilization, micro-biological release testing, and consolidated container loading via Nhava Sheva, Mundra sea ports, or Delhi air cargo (FOB, CIF, or DDP terms).
In-depth, expert answers addressing common technical, regulatory, and commercial inquiries posed by international healthcare buyers.
Our Blood Control Technology IV Catheter features an integrated multi-use silicone septum valve positioned inside the main catheter hub. During venipuncture, the introducer needle passes through this septum. Once the vein is entered and blood flashback is confirmed in the chamber, the clinician withdraws the stylet. As the needle tip clears the hub, the septum automatically closes, sealing the fluid pathway completely.
This internal seal prevents venous blood from leaking out of the catheter hub onto the patient's skin, bedding, or the clinician's hands. When an IV infusion line, extension set, or syringe is connected, the Luer fitting pushes open the internal septum valve to allow unrestricted fluid flow. Unhooking the Luer line causes the valve to instantly reseal, maintaining blood control during line swaps.
While both technologies enhance clinical safety, they solve distinct hazard points in vascular access:
Lars Medicare’s advanced Safety Blood Control Catheters integrate both technologies into a single device, offering 360-degree protection against both sharps injuries and blood-borne pathogen contamination.
Lars Medicare provides a complete Technical Master File formatted for rapid registration with global regulatory authorities (including EU MDR, LATAM ANVISA/COFEPRIS, Middle East SFDA, and African EFDA). Documentation includes:
For standard Lars Medicare branded catalog items, initial shipments can begin at one consolidated pallet. For customized OEM private-label packaging programmes, the MOQ typically ranges between 20,000 to 50,000 units per gauge size, depending on artwork complexity and blister film printing requirements.
Standard production lead time for repeat OEM orders is 3 to 4 weeks. First-time private-label orders require 5 to 6 weeks to accommodate custom packaging proofing, master die setup, cleanroom assembly, EO sterilization incubation, and final QA laboratory release.
Both materials are biocompatible and radio-opaque, but they serve different clinical preferences:
Yes. Lars Medicare is dedicated to patient safety and environmental sustainability. All our Blood Control IV Catheters, Closed System Catheters, IV Infusion Sets, Three-Way Stopcocks, and Extension Tubing are 100% latex-free and can be manufactured using non-phthalate (DEHP-free) PVC or TPE compounds, satisfying strict European pediatric and oncology guidelines.
We work with global Incoterms 2020 including EXW, FOB (Nhava Sheva / Mundra / Delhi Airport), CIF, CIP, and DDP. Cargo is consolidated and palletized directly at our Sonepat manufacturing plant, with complete export documentation (Commercial Invoice, Packing List, Bill of Lading / Airway Bill, Certificate of Origin, and Batch Certificate of Analysis) provided immediately upon dispatch.
Our management team combines decades of medical device manufacturing expertise, clinical engineering knowledge, and global regulatory compliance governance.
20+ years steering disposable medical device manufacturing, cleanroom automation, tool room engineering, and ISO 13485 quality system enforcement.
Directs global export strategies, distributor network expansion, regulatory registration dossiers, and hospital tender support across EMEA, LATAM, and Asia.
Manages client support, supply chain operations, and distribution partnerships from our regional office in Milton, Ontario, Canada.
16–19 November 2026 · Hall 6, Stall No. F37 · Düsseldorf, Germany. Experience live demonstrations of our Blood Control Technology IV Catheters, inspect sample sets, and discuss private label OEM contracts directly with our leadership team.
Expert insights penned by our quality assurance and international regulatory teams to help distributors navigate medical device importing.
Key regulatory checkpoints, technical file structures, and landed-cost strategies when importing IV access devices into European markets.
Previewing our upcoming product launches, including integrated multi-lumen blood control systems, at MEDICA Düsseldorf.
How healthcare procurement officers analyze factory quality systems, sterilization validation, and total cost of ownership over unit prices.
Partner directly with Lars Medicare for factory-direct pricing on Blood Control Technology IV Catheters, safety IV cannulas, and complete vascular access lines. Submit your technical specifications, required gauge mix, and target delivery port for an immediate response from our sales desk.